July 16, 2021 10:40 AM EDTUpdated 04:12 PM

Eli Lilly partner AbCellera finds a CBO in the face of bamlanivimab struggles; FibroGen's next CSO walks into roxadustat rebuff

Kathy Wong

Editor

Alex Hoffman

Copy Chief

→ Covid-19 variants have marred the effectiveness of Eli Lilly and AbCellera’s bamlanivimab to such an extent that the US government stopped using the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Eli Lilly partner AbCellera finds a CBO in the face of bamlanivimab struggles; FibroGen's next CSO walks into roxadustat rebuff

Kathy Wong

Editor

Alex Hoffman

Copy Chief

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Amgen names Stanford geneticist and biotech founder to CSO post

Caltech spinout debuts with AI-driven 'mirror peptide' platform

Are programs with compounded GLP-1s safe for your population?

Eli Lil­ly part­ner Ab­Cellera finds a CBO in the face of bam­lanivimab strug­gles; Fi­bro­Gen's next CSO walks in­to rox­adu­s­tat re­buff

Editor

Copy Chief

Sign up to read this article for free.

Eli Lilly partner AbCellera finds a CBO in the face of bamlanivimab struggles; FibroGen's next CSO walks into roxadustat rebuff